Lipo-B
Common Reported Dosing in Clinical Trials
Survodutide is administered as a once-weekly subcutaneous injection (typically in the abdomen, thigh, or upper arm). Dosing always involves slow titration to improve gastrointestinal tolerability.
Phase 2 obesity trial (46 weeks, no diabetes):
Doses tested: 0.6 mg, 2.4 mg, 3.6 mg, 4.8 mg once weekly.
Mean weight loss (planned treatment): up to -14.9% at 4.8 mg (vs. -2.8% placebo).
In "actual treatment" analysis (accounting for titration): up to -18.7% at 4.8 mg.
Phase 2 MASH trial (48 weeks):
Doses: 2.4 mg, 4.8 mg, 6.0 mg once weekly.
MASH resolution without fibrosis worsening: 47–62% (vs. 14% placebo), with strong liver fat reduction.
Ongoing Phase 3 trials (e.g., SYNCHRONIZE-1/2 for obesity, up to 76 weeks):
Target maintenance doses: 3.6 mg or 6.0 mg once weekly.
Flexible, extended titration schedule (often over 10–20+ weeks) with options to delay increases, reduce by one step, or pause for tolerability (especially GI side effects).
Example titration protocol (adapted from research/vial reconstitution guides; varies by trial and individual tolerance):
Weeks 1–2: 0.6 mg
Weeks 3–4: 1.2 mg
Weeks 5–6: 1.8 mg
Weeks 7–8: 2.4 mg
Weeks 9–10: 3.6 mg
Weeks 11+: Up to 4.8–6.0 mg (if tolerated)
